Introduction {#S0001}
============

Individuals may experience anxiety as a warning sign in unknown situations, especially in response to fear and anticipation of danger.[@CIT0001] However, it is considered pathological when it directly affects the individual's quality of life, affecting social relations, cognitive function, and the wake--sleep cycle.[@CIT0002]--[@CIT0004] Anxiety disorders represent one of the major psychiatric disorders today that can impair the quality of life of adults.[@CIT0002]--[@CIT0004]

The Diagnostic and Statistical Manual of Mental Disorders -- Fifth Edition (DSM-5) defines the presence of an anxiety disorder when some criteria are met, for example: symptoms occurring more than six months, excessive anxiety and worry, panic attacks, restlessness or feeling nervous, fatigue, irritability, sleep and eating disorder. Based on the symptomatology, anxiety disorders can be classified in: Generalized Anxiety Disorder (GAD), Social Anxiety Disorder, Panic Disorder (PD), Agoraphobia, Separation Anxiety Disorder, Selective Mutism and Specific Phobias. In addition to anxiety disorders, anxiety can be a symptom or comorbidity in several other pathologies, such as Major Depression,[@CIT0005] Obsessive Compulsive Disorder,[@CIT0006] TBI,[@CIT0007] among others.

Neuromodulation minimizes the impact of mood changes[@CIT0008]--[@CIT0011] and repetitive transcranial magnetic stimulation (rTMS) is receiving attention in the last decade.[@CIT0012],[@CIT0017] TMS is a non-invasive method of stimulating the motor cortex neurons through the scalp and skull based on the principle of electromagnetic induction.[@CIT0018],[@CIT0019] TMS was approved by the Food and Drug Administration (FDA) in 2008 as an alternative treatment for Major Depression Disorder,[@CIT0020] and has been shown to decrease the symptoms of Post Traumatic Stress Disorder (PTSD),[@CIT0021] Obsessive Compulsive Disorder (OCD),[@CIT0022] and Anxiety Disorders.[@CIT0014]

Non-invasive brain stimulation techniques allow researchers to study in real-time the human brain activity, characterize the balance of excitation and cortical inhibition, and help guide plastic changes.[@CIT0008] With TMS, you can apply repetitive induced current pulses that can increase or decrease cortical excitability and stimulate the process of neuronal plasticity.[@CIT0009],[@CIT0023],[@CIT0024] A coil of wire is placed on the scalp generating an electric current that flows through the target area, inducing neuronal depolarization. Possible effects are depended on subject's age, pharmacological treatment, number of technical parameters, including the intensity and number of stimulations (ie, frequency), coil orientation, focus, and depth of stimulation.[@CIT0009],[@CIT0025],[@CIT0026]

Although TMS pulses (simple and repetitive) are considered safe, it is contraindicated for people who use a pacemaker or other implantable electronic devices.[@CIT0021],[@CIT0027] Patients with bone defects and craniotomy pose another concern, because the conductance of the structures would be modified.[@CIT0021],[@CIT0024] Some adverse effects might occur, such as headache and minor muscle spasms at the stimulation site.[@CIT0021],[@CIT0025],[@CIT0028],[@CIT0029]

Recent literature reviews discussed the use of TMS as an intervention strategy for anxiety. Vicario et al\'s[@CIT0030] study addressed the use of TMS and transcranial direct current stimulation (tDCS) and other studies portray its efficacy for other psychiatric disorders, without major insights.[@CIT0014],[@CIT0030]--[@CIT0032] However, there is a gap in the literature regarding rTMS efficacy in anxiety symptoms (primary and secondary outcomes) in clinical trials. Our study focused on the effectiveness of TMS for Anxiety Disorders and as an intervention for Anxiety Symptoms arising from other pathologies. We make the division between anxiety arising from Neurological Disorders and Psychiatric Disorders. Our hypothesis was that high-frequency rTMS on the dorsolateral prefrontal cortex (DLPFC) will decrease anxiety symptoms in patients with anxiety disorders, considering anxiety as the primary outcome.

Methods {#S0002}
=======

We conducted a literature online search including Web of Science Medline/PubMed MEDLINE databases. We have included publications from any time until March 2019. We included clinical trial and open-label using the keywords: "TMS", "transcranial magnetic stimulation", "noninvasive brain stimulation", and "anxiety". The first exclusion was by title and followed by abstracts and full texts. Abstracts and full text, and studies were included if fulfilled, the inclusion criteria: (a) use of rTMS as intervention; (b) anxiety was assessed as primary or secondary outcome; (c) sample was adults; (d) published in peer-review journals; (e) full text written in English. The exclusion criteria: (a) animal studies; (b) case report; (c) systematic review or meta-analysis; (d) paper not written in English; (e) study with healthy; and (f) studies that did not report the use of rTMS in anxiety symptoms. Searching and data analysis were performed by Rodrigues PA and Zaninotto AL. This method follows PRISMA guidelines.

Results {#S0003}
=======

[Figure 1](#F0001){ref-type="fig"} shows the systematic review that initially 358 papers were found (Pubmed =172; Web of Science =186). We found 32 studies that fulfilled our eligibility criteria.Figure 1Flow diagram of the papers selected in our study, following PRISMA statement guidelines.

For a better understanding of the results, we divided the target population of the trials in two categories: Category 1) patients with Anxiety Disorders, according to DSM-5 ([Table 1](#T0001){ref-type="table"}); Category 2) Anxiety symptoms, from neurological and psychiatric disorders that also evaluated anxiety symptoms as comorbidity ([Table 2](#T0002){ref-type="table"}).Table 1Patients with anxiety disorders, according to DSM 5Author/YearPatient/Sham groupDiagnosisStudy designTarget\# of rTMS sessionsFrequencyPulses per sessionStimulation intensityNP testsRelevant results following treatmentTolerability and safetySustained effect of responseZhang, 2019[@CIT0037]117 rTMSMood or Anxiety DisordersRCTLeft DLPFC1010 Hz2400120% of RMTHAMAAll the age groups showed significant improvements in clinical symptomsNo safety or tolerability concerns were identifiedYes for adolescents, but not in adultsLu R, 2018[@CIT0038]28 rTMSGADOpen-labelRight DLPFC + left DLPFC101 Hz75080% of RMTHRSAIn this study, low-frequency rTMS which was successively delivered to right and left DLPFC effectively alleviated anxiety symptoms in GAD patientsAll patients tolerated rTMS well without any adverse effectsYesDilkov D, 2017[@CIT0033]9 rTMS/12 shamGADRCTRight DLPFC2520 Hz3600110% of RMTHRSAParticipants receiving rTMS showed clinically significant decrease in reported anxiety symptoms.One participant in the active group had seizure; transient dizziness was reported in three patientsYesDiefenbach GJ, 2016[@CIT0035]13 rTMS/12 shamGADRCTRight DLPFC301 Hz90090% of RMTHRSA; DASSANOVA demonstrated significant group x time interaction for the primary and secondary outcomes with the gains maintained only in the rTMS group at follow-up.No seizures occurred; mild adverse effects were reported and was similar in rTMS and sham groupsYesWhite D and Tavakoli S, 2015[@CIT0005]13 rTMSComorbid MDD and GADOpen-label, pilot studyRight DLPFC + left DLPFC24361Hz (right side)+10hz (left side)1000NRGAD-7Paired *T*-test comparing baseline to final scores showed a markedly significant difference for both GAD-7 and the HDRS-21, suggesting a decrease of 65% and 75% in depression and anxiety, respectively.NRNot applicableMantovani A, 2013[@CIT0034]12 rTMS/13 shamPD and comorbid MDDRCT. Two phases: Phase I 4-week double-blind followed by Phase II (optional) 4-week open-labelRight DLPFCPhase I: 20; Phase II: 201Hz1800110% of RMTPDSS; HRSA-14Repeated-measures ANOVA revealed a significant time by group interaction with PDSS, with greater reduction in active group.No seizures were reported. None of the patients reported significant side effectsYesPrasko J, 2007[@CIT0036]7 rTMS/8 shamPD or PD with agoraphobiaRCTRight DLPFC101 Hz1800110% of RMTHRSA; BAI; PDSSNo statistical difference between groups were observed after treatment.No seizures, headaches, neurological and cognitive decline occurredNot applicable[^1] Table 2Anxiety symptoms, from neurological and psychiatric disordersAuthor/YearPatient/Sham groupDiagnosisStudy designTarget\# of rTMS sessionsFrequencyPulses per sessionStimulation intensityAnxiety questionnairePrimary outcomeRelevant results following treatmentTolerability and safetySustained effect of responseKaur M, 2019[@CIT0039]16 rTMSMood disordersOpen-labelLeft DLPFC2010 HzNR110% of RMTAnxiety subscale of the HDRSTo determine whether sleep--wake disturbance, cognition or depression chronicity are associated with rTMS outcome in young depressed adultsShow reduced depressive and anxiety symptoms and no cognitive deteriorationNRYesLin H, 2018[@CIT0040]7 rTMSThalamic painOpen-labelMotor cortex1010 Hz100090% of RMTHAMATo evaluate the analgesic lasting effect to treat thalamic painHigh-frequency rTMS can provide long-term pain relief in patients\
with thalamic painAll patients tolerated rTMS well with out any adverse effectsNoReyes-Lopez. J, 2018[@CIT0041]29 rTMSBorderlineRCTRight DLPFC + left DLPFC155 Hz or 1 Hz900 or 1500100% of RMTHRSATo evaluate\
clinical improvement in patients with BPD after application of rTMSHAM-A scores reduced after rTMS treatment. Both protocols produced global improvement in severity and symptoms of BPD, particularly in impulsiveness, affective instability, and angerNRYesDurmaz O, 2017[@CIT0042]36 rTMSMDDOpen-labelLeft DLPFC1520 Hz1000110% of RMTHRSATo evaluate the efficacy of rTMS in patients with treatment-resistant major depressionThe findings suggested that comorbid anxiety symptoms, particularly somatic anxiety, could predict the response to rTMS in treatment-resistant major depressive disorderHeadache in eight patients, dizziness in four patients, and lacrimation in three patients. Only one patient dropped out of the study due to side effects or intoleranceYesNoh TS, 2017[@CIT0043]17 rTMSTinnitusRCTLeft auditory cortex (AC) and left DLPFC or only the left DLPFC41 Hz2000 or 3000110% of RMTSTAIWe evaluated treatment outcomes following single-site rTMS in the DLPFC and dual-site\
rTMS in the AC and DLPFCGroup 1 exhibited significant improvements in scores on the STAI for both state anxiety and trait anxiety at 12 weeks posttreatment.\
Group 2 showed an improvement in only the STAI-X2 score at 12 weeks posttreatment.NRNoTovar-Perdomo S, 2017[@CIT0044]24 rTMSMDDOpen-label, pilot studyLeft DLPFC2010 Hz3000120% of RMTBAITo explore the effects of a course of accelerated high-frequency rTMS on two neurocognitive domains in patients with MDDDepression and anxiety scores significantly improved from pre-post HF-rTMS treatment.The absence of practice effects in our longitudinal design raises the possibility that rTMS may also have cognitive side effects which, like antidepressant effects, may recede and reveal cognitive improvements after treatment cessation and sustained recoveryNoElbeh KAM, 2016[@CIT0006]30 rTMS/15 shamOCDRCTRight DLPFC + left DLPFC101 Hz or 10 Hz200 or 500100% of RMTHRSATo evaluate the impact of different frequencies of rTMS in OCD1 Hz rTMS over the right DLPFC has medium-term effect on\
obsessive-compulsive symptoms and anxietyAll patients tolerated rTMS well without any adverse effects except for two patients in the active stimulation group who experienced transient headache that disappeared with in a few hoursYesMalavera A, 2016[@CIT0045]27 rTMS/27 shamPainRCTPrimary Motor Cortex contralateral to the amputated leg1010 Hz120090% of RMTZung Self-Rating Anxiety ScaleThe score change in the Visual Analogue Scale for painNo statistically significant between-group difference was found when\
comparing the absolute scores of the depression and anxiety scales at day 15 or day 30Some patients experienced minor adverse effects such as headache, neck pain, and sleepiness without significant differences between groupsYesBilici S, 2015[@CIT0046]45 rTMS/30 shamTinnitusRCTLeft temporoparietal region101 Hz or 10 Hz600 or 900110% of RMTBASTo compare the effects of rTMS and paroxetine on tinnitus in terms of effectiveness and medium-term resultsThe positive effects that were observed might reflect a relationship between tinnitus and auditory cortex areas related to emotionsIn the 10 Hz TMS treatment group, two patients complained of neck and shoulder stiffness, which disappeared in 2 days without any medical treatment; two patients had jaw fasciculation, which continued for 1 hr; and one patient had a headache for 1 day. One patient in the 1 Hz rTMS group had mild jaw pain for 2 days. All patients in the paroxetine-treated group were asked to report possible side effects of the drug. Among those, three had cephalalgia, two had gastrointestinal disorders, and one had sexual dysfunction; all these side effects were mild-to-moderate in intensity and did not delay the therapyYesLin YC, 2015[@CIT0047]14 rTMSRLSOpen-labelMotor cortex area of the frontal lobe1415 Hz600100% of RMTHRSATo investigate whether rTMS could have any beneficial effects in restless legs syndromerTMS can markedly alleviate the motor system symptoms, sleep disturbances, and anxiety in RLS patientsNo adverse effects were observed during stimulation or after treatment, and all patients showed good complianceYesOznur T, 2014[@CIT0048]20 rTMSPTSDOpen-labelRight DLPFC201 HzNR80% of RMTBAITo examine the effectiveness of rTMS in patients with treatment-resistant posttraumatic stress disorderThe effectiveness of rTMS on the anxiety and depression scores in the patients was not determined in this studyNRNoDiefenbach GJ, 2013[@CIT0049]32 rTMSMDDOpen-labelLeft DLPFC3110 Hz3000--500080 at 130% of RMTAnxiety/somatization subscale of the HDRSTo determine if anxious depression is associated with attenuated response to rTMSBoth depression and anxiety symptoms improved from pre- to post-treatment with moderate to large treatment effectsNRYesPretalli JB, 2012[@CIT0050]75 rTMSMDDRCTLeft DLPFC1010 HzNR95% of RMTHAMD anxiety subscale (items 9, 10, 11, and 15); Tyrer scale for anxiety; STAITo investigate whether or not RMT changes during the treatment of resistant depressionThese RMT changes influenced the outcome of the 10 sessions concerning the severity of depressive and anxiety symptomsOnly mild side-effects were reported (pain at the site of the coil placement or headache)YesSun W, 2012[@CIT0051]60 rTMSFocal epilepsyRCTEpileptogenic focus100.5 Hz150090% or 20% of RMTSCL-90To evaluate the therapeutic effect of low-frequency rTMS on patients with refractory partial epilepsyAll the subscale scores of somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, paranoid ideation and psychoticism in group 1 was lower than that of group 2 when evaluated at the end of follow-up periodThe most common adverse events were mild or moderate headache and tinnitus. Adverse events occurred more often in group one patients who received "90% rMT" rTMSYesWatts BV, 2012[@CIT0021]10 rTMS/10 shamPTSDRCTRight DLPFC101 HzNR90% of RMTSTAIThis study seeks to examine the efficacy of rTMS for PTSDAnxiety symptoms showed improvement with rTMS, but those improvements were not statistically significant compared with shamNRYesBerlim MT, 2011[@CIT0052]15 rTMSMDDOpen-labelLeft DLPFC2010 Hz3000120% of RMTHRSA; BAITo address an augmenting strategy in subjects with chronic, severely treatment-resistant MDDClinically meaningful improvements in anxious and depressive symptomsOnly one of the 15 participants withdrew from the study at week 1 because of lack of tolerability (ie, severe scalp pain)YesBoggio PS, 2010[@CIT0053]20 rTMS/10 shamPTSDRCTRight DLPFC or left DLPFC1020 Hz160080% of RMTHRSATo investigate the efficacy of rTMS for the relief of posttraumatic stress disorder (PTSD)-associated symptomsRight rTMS generated a significant improvement in the measure of anxiety at days 5 and 10 while left rTMS did notThere were no seizures and only mild adverse effects, such as mild headache, neck pain, sleepiness, and dizziness were reported similarly in the 3 groups of treatmentYesEpstein CM, 2007[@CIT0054]14 rTMSParkinson diseaseOpen-labelLeft DLPFC1010 Hz1000110% of RMTHRSATo investigate about rTMS as a potential treatment for depression in PD and for the movement disorder of PDOpen rTMS treatment of PD patients with treatment-resistant depression was followed by highly significant improvement in mood scores and anxiety ratingsThere were no seizures and no complaints of headache or neurological deteriorationYesPassard A, 2007[@CIT0055]15 rTMS/15 shamFibromyalgiaRCTLeft primary motor cortex1010 Hz200080% of RMTHospital Anxiety ScaleTo assess the effects of unilateral rTMS of the motor cortex on chronic widespread pain in patients with fibromyalgiaThe analgesic effects were observed from the fifth stimulation onwards and were not related to changes in mood or anxiety.Minor and transient side effects were reported during the stimulation period only. Nine patients reported headaches: four in the active-stimulation group and five in the sham stimulation group. These headaches, reported after only 1 of the 10 daily sessions, were mild and transient in all cases. Other side effects included nausea after the fifth session in one patient in the active-treatment group. Two patients reported transient tinnitus and one patient reported mild dizziness after one sham-stimulation sessionYesRossi S, 2007[@CIT0056]14 rTMSTinnitusOpen-labelLeft temporoparietal region51 Hz1200120% of RMTHRSATo assess about rTMS on chronic tinnitus in which also eventual mood changes are monitoredIn patients with chronic tinnitus, psychiatric comorbidity as mood or anxiety disorders are relevant and may partly found their functional counterpart in the activation of higher-order processingThe majority of patients did not complain of side effects due to rTMS, a part a slight transient headache on the stimulation site, which however did not require pharmacological treatment. About 30% of patients complained of tongue paraesthesia occurring during the active rTMS. Most of patients reported a transient worsening of their tinnitus in the first two--three days of active rTMS. Two male patients, one receiving active rTMS and one sham rTMS as first intervention, dropped ut from the study for this reasonYesCohen H, 2004[@CIT0057]18 rTMS/6 shamPTSDRCTRight DLPFC101 Hz or 10 HzNR80% of RMTHRSATo evaluate the therapeutic effects of two different frequencies of active rTMS of PTSD patientsActive 10-Hz rTMS, relative to 1-Hz treatment and sham, significantly reduced Hamilton anxiety scale scores but not Hamilton depression scale scoresHeadache was the main side effect reported, regardless of stimulation group. It was reported by 14 patients: eight patients reported headache after one rTMS treatment, five patients reported it after two sessions, and one (receiving sham treatment) reported it after three sessions. In most cases, this side effect was reported several hours after the stimulation or on the following morning. Only four patients reported headache immediately after the stimulation. In three cases, headache was a symptom before the study. However, the total number of headaches after treatment was 21. Two patients receiving high-frequency rTMS reported neck pain and muscular contraction in the area. Another patient receiving high-frequency treatment reported an exacerbation of previously existing dizziness. One patient in the group receiving slow-frequency rTMS and one patient from the high-frequency group developed a manic episode; in both cases, this occurred after the third session of rTMS. One patient reported a mild rage attack, probably related to the stimulation. Although we did not use earplugs, only two patients reported ear discomfort, which lasted less than 1 minYesLoo CK, 2003[@CIT0058]18 rTMSMDDRCTLeft DLPFCNR15 Hz or 1 HzNR90% of RMT7-item scaleTo understand further the mechanisms of action of high- and low-frequency rTMS by examining their acute effects on regional cerebral blood flow (rCBF) in depressed patientsAnxiety scores did not differ between the 15 Hz and 1 Hz groups. rTMS can produce functional changes in areas of the brain involved in mood control, including changes tending toward correction of deficits associated with depressionNRYesMünchau A, 2002[@CIT0059]12 rTMSGTSOpen-labelLeft premotor61 Hz120080% of RMTHospital Anxiety ScaleTo study whether rTMS targeted to left motor and premotor cortex can improve tics in GTSThere was no significant improvement of symptoms after any of the rTMS conditions as assessedOne patient reported mild headache after premotor rTMS. Two patients reported excessive tiredness after both premotor and motor rTMS lasting for about 1 dayYesGeorge MS, 2000[@CIT0060]20 rTMS/10 shamMDDRCTLeft prefrontal cortex105 Hz or 20 HzNR100% of RMTHRSATo conduct a study to address whether 2 weeks of daily TMS over the left prefrontal cortex has antidepressant activity greater than shamExpressed as a percent change from baseline, active TMS subjects had significantly greater improvement on the BDI as well as the HARS than did those who received shamTwo subjects with average MTs (60% and 70% of machine output) elected to stop the study because of the pain of stimulation. One subject tried for 2 consecutive days, whereas the other decided to stop after only 2 mins of the first session. Ten subjects reported mild headaches following at least one session (beginning immediately after to 3 hrs after rTMS), which were relieved by acetaminophenYesRollnik JD, 2000[@CIT0061]6 rTMS/6 shamSchizophreniaRCTLeft DLPFC1020 Hz80080% of RMTSTAITo investigate the therapeutic efficacy of rTMS in schizophrenic patients with acute exacerbation of their psychosisSTAI, BDI, and NCT scores tended to improve during active rTMS and to worsen during sham stimulation, but the observed changes were not significant.NRYes[^2]

Treatment for anxiety disorders {#S0003-S2001}
-------------------------------

In our search, five studies were randomized double-blind clinical trial (RCT) and two studies were open-label. Seven papers described Anxiety Disorders as the main outcome for rTMS,[@CIT0005],[@CIT0033]--[@CIT0038] one was related to Anxiety Disorders, two were Panic Disorder (PD), and the other four were GAD ([Table 1](#T0001){ref-type="table"}). The sample size of these studies ranged from 13 to 25 patients.

The right dorsolateral prefrontal cortex (DLPFC) was the most frequent stimulation region and in one study they stimulated the left region of the DLPFC. The predominant frequency used was 1 Hz, although one study compared the use of 1 hz and 10 hz and another used only 20 Hz.

The number of sessions ranged between 10 and 30 and the number of pulses per stimulation ranged from 750 to 3600. Most papers used an intensity of 110% of the rest motor threshold (RMT), one used 80% and other used 90% of RMT and one study did not specify.

Treatment for other psychiatric neurological diseases {#S0003-S2002}
-----------------------------------------------------

We found 23 studies reporting rTMS as an alternative for the treatment of neurological or psychiatric disorders and as secondary intervention to anxiety symptoms ([Table 2](#T0002){ref-type="table"}).[@CIT0006],[@CIT0021],[@CIT0039]--[@CIT0061]

Papers that cited symptoms of anxiety as comorbidity were grouped in Neurological Disorders ([Table 3](#T0003){ref-type="table"})[@CIT0040],[@CIT0045],[@CIT0047],[@CIT0051],[@CIT0054],[@CIT0055],[@CIT0059] and Psychiatric Disorders ([Table 4](#T0004){ref-type="table"}).[@CIT0006],[@CIT0021],[@CIT0039],[@CIT0041]--[@CIT0044],[@CIT0046],[@CIT0048]--[@CIT0050],[@CIT0052],[@CIT0053],[@CIT0056]--[@CIT0058],[@CIT0060],[@CIT0061] We found that MDD is the psychiatric disorder with the highest occurrence appearing in seven papers while pain is the highest Neurological Disorders occurrence appearing in three papers.Table 3Symptoms of anxiety present in neurological disordersPrimary pathologyNumber of studiesPain3 (Lin et al, 2018[@CIT0040] Malavera et al, 2016[@CIT0045] Passard et al, 2007[@CIT0055])Restless Legs Syndrome1 (Lin et al, 2015[@CIT0047])Focal epilepsy1 (Sun W, 2012[@CIT0051])Parkinson's disease1 (Epstein et al, 2007[@CIT0054])Gilles de la Tourette Syndrome1 (Münchau et al, 2002[@CIT0059])

Fourteen papers reported the stimulation in the left DLPFC, three papers both left and right DLPFC and in one study the left auditory cortex was stimulated. Two papers focused the stimulation in the left temporoparietal region and left primary motor cortex. The stimulation target of right DLPFC appeared in three papers, in addition to those already mentioned. These regions were stimulated in one paper each: primary motor cortex contralateral to the amputated leg, motor cortex area of the frontal lobe, and the epileptogenic focus. Two studies described stimulation in the left temporoparietal region and left primary motor cortex.

High pulse frequency (\>5 Hz) used in rTMS protocols can have an excitatory effect while a low frequency (1 Hz) has an inhibitory effect. These effects are not limited to the target of stimulation, favoring the improvement of mood symptoms since there is complex connectivity of the cerebral cortex with other deep brain regions, favoring, ultimately, the improvement of mood symptoms. Most studies analyzed in this review used 10 stimulation sessions and half used excitatory stimulation for all subjects with rTMS frequency range between 5 Hz and 20 Hz. In the treatment of anxious symptoms, studies reported using between 4 and 31 sessions with 200--5000 pulses per stimulation and an intensity of 20--130% of the RMT.

Measures of anxiety symptoms {#S0003-S2003}
----------------------------

One of the criteria used to include the paper in our systematic review was to contain measures to assess the symptoms of anxiety pre and post rTMS sessions. The Hamilton Rating Scale for Anxiety (HRSA) was the main scale found in this review; overall, this scale appeared in 14 papers; secondly the Beck Anxiety Inventory (BAI) and the State-Trait Anxiety Inventory (STAI), both appearing in four papers. In [Table 5](#T0005){ref-type="table"}, we observe the other scales of assessment of the symptoms of anxiety found and their frequency in the papers.Table 4Symptoms of anxiety present in psychiatric disordersPrimary pathologyNumber of studiesBorderline1 (Reyes-Lopez. J et al,2018[@CIT0041])MDD8 (Kaur et al, 2019[@CIT0039] Durmaz et al, 2017[@CIT0042] Tovar-Perdomo et al, 2017[@CIT0044] Diefenbach et al, 2013[@CIT0049] Pretalli et al, 2012[@CIT0050] Berlim et al, 2011[@CIT0052] Loo et al, 2003[@CIT0058] George et al, 2000[@CIT0060])Tinnitus3 (Noh et al, 2017[@CIT0043] Bilici et al, 2015[@CIT0046] Rossi et al, 2007[@CIT0056])Obsessive Compulsive Disorder1 (Elbeh et al, 2016[@CIT0006])Post Traumatic Stress Disorder4 (Oznur et al, 2014[@CIT0048] Watts et al, 2012[@CIT0021] Boggio et al, 2010[@CIT0053] Cohen et al, 2004[@CIT0057])Schizophrenia1 (Rollnik et al, 2000[@CIT0061])[^3] Table 5Anxiety scales found in papersAnxiety questionnaire papersNumber of citationsHRSA15BAI4STAI4Hospital Anxiety Scale2PDSS2Anxiety/somatization subscale of the HDRS2HAMA27-item scale1BAS1DASS1GAD-71HAMD anxiety subscale (items 9, 10, 11 and 15)1SCL-901Tyrer scale for anxiety1Zung Self-Rating Anxiety Scale1[^4]

Clinical findings {#S0003-S2004}
-----------------

We observed, in general, that most of the studies found satisfactory results with the use of rTMS in Anxiety Disorders and Anxiety as comorbidity.

In the studies on Anxiety Disorders, it was observed that three papers reported a sustained effect of response on the improvement of anxious symptoms, one paper reported improvement of symptoms, although this response did not sustain in the long term and one paper reported that there was no significant improvement.

The papers on Anxious Symptoms showed that most of the studies obtained the sustained effect of response on the anxiety symptoms observed in 21 studies. Two studies showed improvement but not sustained over time and one of them did not find a positive response to the improvement in anxiety symptoms.

Tolerability and safety {#S0003-S2005}
-----------------------

Adverse effects were minimal, showing that there is safety in the application of rTMS in anxious symptoms independent of the primary outcome.

In the papers on Anxiety Disorders, only one study reported that one participant in the active group had seizures and three participants reported transient dizziness; in the other papers, no adverse effects were reported.

In the papers on Anxious Symptoms, mild side effects were observed. The most frequent effect was a headache that appeared in 12 studies. In two studies, some patients were withdrawn because of side effects or treatment intolerance. [Table 6](#T0006){ref-type="table"} has the description and frequency of other side effects found in the papers on Anxious Symptoms.Table 6Side effects of rTMS found in papersSide effectsFrequency in papersDizziness4Pain and stiffness in the neck and shoulder2Ringing in the ear3Drowsiness2Tearing1Regression in cognitive improvement during treatment1Neck pain1Fasciculation and mandibular pain1Gastrointestinal disorders1Sexual dysfunction1Muscle contraction1Rage attack1Ear discomfort1Excessive fatigue1

Discussion {#S0004}
==========

The rTMS is already established as a non-invasive valid alternative to measure plastic alterations of the cerebral cortex for the treatment of depression,[@CIT0002] borderlines,[@CIT0041] OCD,[@CIT0006] among other pathologies. We observed in this review that anxiety is one of the main symptoms related to current mood disorders, with a direct impact on individuals' quality of life.[@CIT0007]

TMS have a direct correlation between the parameters associated with cortical excitability and plasticity, suggesting the existence of mechanisms that partially overlap and probably act in the same neurophysiological framework.[@CIT0062]

Pennisi et al suggest that lesion in the ischemic subcortical and prefrontal region might have implications in cognition and mood and may result in functional changes of the intracortical system, in addition to associating an increase in global cortical excitability, together with a significant worsening of frontal lobe abilities, but without substantial functional impairment.[@CIT0062]

Cortical plasticity plays a clear and fundamental role in patients with depression, while this still seems to be firmly established in anxiety disorders.[@CIT0063]

Studies observed that impaired brain plasticity may be one of the pathophysiological mechanisms underlying cognitive decline and major depression.[@CIT0063] Some degree of cognitive impairment is often observed across the clinical spectrum of mood disorders, and between depression and cognition often bidirectional.[@CIT0063] Depressed patients have significant differences between the brain hemispheres, the intracortical neurochemical circuit (inhibitory or excitatory) might be unbalanced, the excitability of the motor cortex and TMS may indicate a disruption of plasticity.[@CIT0063] The data suggest that the motor cortex is more refractory to modulatory inputs from other non-motor areas within the CNS in depressed individuals.[@CIT0063] In addition, several studies have shown that functional abnormalities in cortical connections may play crucial roles in patients with depression and other mood disorders.[@CIT0063]

Studies with depressive disorder usually predict anxiety symptoms as a secondary outcome. It is possible to observe how this mechanism occurs in cases of anxiety disorders, since it is directly related to the functioning of neurotransmitters and to the cerebral circuits. TMS may interfere directly in this functioning and may influence the regulation of anxiety as a symptom arising from another psychopathology or as an anxiety disorder.[@CIT0063]

Other studies[@CIT0014],[@CIT0030],[@CIT0032] have found that TMS have promising results as a treatment for anxiety disorders; we observed comparable results, showing TMS intervention having positive effects on anxiety symptoms. However, there is still no standard intervention protocol for the use of TMS, neither for anxiety or depression disorders, as a comorbidity of psychiatric and neurological disorders.[@CIT0014],[@CIT0030],[@CIT0032]

A few studies describe protocols for TMS application on anxiety disorders, Dilkov et al[@CIT0033] evidenced the effects of rTMS on participants with GAD. Most participants who received treatment from 25 rTMS sessions had a clinically significant decrease in anxiety symptoms as identified by the efficacy symptom scale.[@CIT0033]

Another study also observed positive results in subjects with GAD after 30 rTMS sessions according to pre- and post-treatment comparative assessment scales.[@CIT0035] However, the Sham coil group also had reduced anxiety symptoms; they had a limited sample size and further assessment is necessary.[@CIT0035]

The authors used 2 sessions of rTMS in the prefrontal ventromedial cortex region for the treatment of Acrophobia and fear of irrational stature.[@CIT0064] Their study used virtual reality technology to assist in the therapy and they observed a better response for fear and symptoms.[@CIT0064]

There is no clear pattern for using high or low frequencies of TMS stimulation in which regions of the brain. One review study cited the use of both high- and low-frequency TMS stimulation under the right and left stimulation target DLPFC.[@CIT0030] Iannone et al[@CIT0014] cited papers that used both high and low frequencies of TMS on anxiety disorders. Another review study found that the right and left DLPFC were targets for TMS stimulation in most papers.[@CIT0031] However, when searching for anxiety as a secondary outcome, the stimulation region was dependable on the primary outcome of the TMS intervention. TMS stimulation for pathologies involving motor aspects poses another difficulty.[@CIT0065] In these cases, the stimulation target was primarily in specific regions of the motor cortex.[@CIT0065]

Patients with Restless Legs Syndrome (RLS) who receive TMS intervention had improvements on anxiety symptoms with the improvement of the RLS symptoms.[@CIT0047] A similar study found that using TMS to stimulate the motor cortex area alleviated motor sensory complaints of RLS patients. TMS excitation and inhibition rates indicate intracortical injury and corticospinal imbalance, involving GABAergic and glutamatergic circuits, as well as impairment of the short-term mechanisms of plasticity.[@CIT0065] The activation induced by rTMS with the consequent increase in dopamine release may have contributed to the clinical and neurophysiological outcome in those patients.[@CIT0065] The occurrence of anxiety in patients with RLS is related to an abnormal sensorimotor integration, suggesting an interrupted connectivity in the RLS.[@CIT0066] Using TMS in the sensory cortex motor region may promote improvements of physical symptoms and therefore reduction in anxiety.[@CIT0066]

TMS has also been shown to be effective as a sustained response effect compared to drug intervention. It is observed that drug-resistant patients on MDD treatment achieved improvement of symptoms with the use of TMS after a period of six months post-intervention, while this period is reduced when only medication is used.[@CIT0067]

Although there is no consensus in the TMS intervention parameters for anxiety disorders and symptoms due to neurological or psychiatric disorders, we observed that the DLPFC region is preferred among researcher's stimulation target. TMS have promising results in high frequency, promoting excitatory stimulation, and low frequency, promoting inhibitory stimulation. The number of sessions should range from 10 to 20 sessions so that the sustained response effect is possible. The stimulation of the motor cortex, especially in the sensorimotor region, also shows promising results in the stimulation of anxiety symptoms due to neurological disorders, mainly focusing on motor aspects.

Conclusion {#S0005}
==========

We observed in this review that TMS might be a satisfactory intervention measure to improve anxiety, although there are a limited number of reports on the use of this intervention. In addition, satisfactory results have also noted that TMS is a safe treatment strategy with low side effect. Further studies using TMS could direct the treatment with psychological or psychiatric intervention.
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[^1]: **Abbreviations:** BAI, Beck Anxiety Inventory; DASS, Depression Anxiety Stress Scales; DLPFC, Dorsolateral Prefrontal Cortex; GAD, Generalized Anxiety Disorder; GAD-7, Generalized Anxiety Disorder scale; HAMA, Hamilton Rating Scale for Anxiety; HRSA, Hamilton Rating Scale for Anxiety; MDD, major depressive disorder; NP, neuropsychological; NR, Not Reported; PD, Panic Disorder; PDSS, Panic Disorder Severity Scale; RCT, Randomized Controlled Trial; RMT, Resting Motor Threshold; rTMS, repetitive Transcranial Magnetic Stimulation.

[^2]: **Abbreviations:** STAI, State-Trait Anxiety Inventory; HRSA, Hamilton Rating Scale for Anxiety; BAI, Beck Anxiety Inventory; HAMA, Hamilton Rating Scale for Anxiety; RMT, Resting Motor Threshold; rTMS, repetitive Transcranial Magnetic Stimulation; DLPFC, dorsolateral prefrontal cortex; MDD, major depressive disorder; PTSD, Post Traumatic Stress Disorder; RLS, Restless Legs Syndrome; OCD, Obsessive Compulsive Disorder.

[^3]: **Abbreviation:** MDD, major depressive disorder.

[^4]: **Abbreviations:** HRSA, Hamilton Rating Scale for Anxiety; BAI, Beck Anxiety Inventory; STAI, State-Trait Anxiety Inventory; PDSS, Panic Disorder Severity Scale; HAMA, Hamilton Rating Scale for Anxiety; DASS, Depression Anxiety Stress Scales; GAD, Generalized Anxiety Disorder.
